BVD-523; VRT752271 MedChemExpress (MCE)

Product Name	4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
Synonyms	VRT752271 Ulixertinib VRT752271 HCl VRT-752271(Ulixertinib) Ulixertinib (BVD-523,VRT752271) 4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Synonyms VRT752271 Ulixertinib VRT752271 HCl VRT-752271(Ulixertinib) Ulixertinib (BVD-523,VRT752271) 4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide 1H-Pyrrole-2-carboxaMide, 4-[5-chloro-2-[(1-Methylethyl)aMino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- 4-[5-Chloro-2-[(1-methylethyl)amino]-4-pyridinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide VRT752271
CAS	869886-67-9
EINECS
Chemical Formula	C21H22Cl2N4O2
Molecular Weight	433.33098
inchi
Package	10 mM * 1 mL;1 mg;5 mg;10 mg;50 mg
Price	Email to quote
Descriptions	Ulixertinib Ulixertinib MedChemExpress (MCE) HY-15816 869886-67-9 BVD-523 Descriptions Ulixertinib Ulixertinib MedChemExpress (MCE) HY-15816 869886-67-9 BVD-523 VRT752271 99.95% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. Ulixertinib (BVD-523 VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of ERK2. Ulixertinib (BVD-523 VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line. Combined Ulixertinib (BVD-523 10, 20, 30 μM 48 hours) and VS-5584 treatment causes significant induction of cell death in human pancreatic cancer (HPAC) cells in PDAC cell lines BxPC-3, MIAPaCa-2, and CFPAC-1[3]. In the pharmacokinetic study, the sensitivity and specificity of the assay are found to be sufficient for accurately characterizing the plasma pharmacokinetics of Ulixertinib (VRT752271) in Balb/C mice[2]. ERK2 0.3 nM (IC50, at KM ATP (60 μM)) ERK1 \| \| \| \| \| \| \| \| \| \| [1]. Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11 58(11):4790-801. [Content Brief] [2]. Kumar R, et al. Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2016 Jun 5 125:140-4. [Content Brief] [3]. Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4 8(27):44295-44311. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact